Mikrobiyota ve Yoğun Bakım

PEHLİVANLAR Küçük, Mehtap; Ülger, Fatma

doi:10.4274/tybd.galenos.2019.70883

Mikrobiyota ve Yoğun Bakım

Mehtap PEHLİVANLAR KÜÇÜK, (Ondokuz Mayıs Üniversitesi)

Fatma ÜLGER (Ondokuz Mayıs Üniversitesi)

Türk Yoğun Bakım Dergisi

6 0

Yıl: 2019 Cilt: 17 Sayı: 3 Sayfa Aralığı: 122 - 129 Metin Dili: Türkçe DOI: 10.4274/tybd.galenos.2019.70883 İndeks Tarihi: 20-04-2020

Mikrobiyota ve Yoğun Bakım

Öz:

İnsan vücudunda birçok organ ve dokuda kolonize olmuş toplam 1014 mikroorganizma olduğutahmin edilmektedir. İnsan vücudunda trilyonlarca, neredeyse konak hücrelerin 10 katı kadar bakteriolduğu tahmin edilmektedir. Mikrobiyom olarak tanımladığımız bu yeni yaşam birliğinin klinik öncesiçalışmalarda, çok sayıda doğrudan ve dolaylı (immün aracılı) mekanizma yoluyla enterik ve sistemikpatojenlere karşı korunmada esas oldukları gösterilmiştir. Barsak mikrobiyotasının homeostazisindekidengesizlik veya disbiyozis, diyabet, obezite, enflamatuvar barsak hastalığı ve romatoid artrit gibi birdizi farklı hastalık ile ilişkilendirilmiştir. Genel olarak, yoğun bakım ünitesinde (YBÜ) sepsis ile takiplihastalarda barsak mikrobiyotası, daha düşük çeşitlilik, anahtar kommensal türlerin (Faecalibacterium,Blautia, Ruminococcus gibi) azalması ve Escherichia, Shigella, Salmonella, Enterococcus, C. difficileveya Staphylococcus gibi cinslerde artışla karakterizedir. Mevcut tedavi yöntemleri, iki prensibedayanmaktadır; ya potansiyel olarak patojenik mikroorganizmaların (dekolonizasyon stratejileri) aşırıçoğalmasını azaltmak ya da faydalı mikroorganizma havuzunu yeniden tedarik etmektir. Diğer tümalanlarda olduğu gibi YBÜ’de de mikrobiyota hedefli tedavi stratejileri hakkında araştırmalar devametmektedir.

Anahtar Kelime:

Konular: Biyoloji

Microbiota and Intensive Care

Öz:

It is estimated that there are a total of 1014 microorganisms colonized in many organs and tissues in the human body. It is also estimated that there are trillions of bacteria in the human body, almost 10 times that of host cells. This new life association, which we define as microbiomes, has been shown to be essential for protection against enteric and systemic pathogens through many direct and indirect (immunologically mediated) mechanisms in preclinical studies. Dysbiosis or imbalance in the homeostasis of the intestinal microbiota has been associated with many different diseases such as diabetes, obesity, inflammatory bowel disease and rheumatoid arthritis. In general, intestinal microbiota in patients with sepsis following intensive care unit (ICU) follow-up is characterized by lower diversity and commensal species (such as Faecalibacterium, Blautia, Ruminococcus) and an increase in strains such as Escherichia, Shigella, Salmonella, Enterococcus, C. difficile or Staphylococcus. Current treatment methods are based on two principles, either to reduce the excess proliferation of potentially pathogenic microorganisms (decolonization strategies) or to re-supply the pool of beneficial organisms. As in all areas, research on microbiota-targeted treatment strategies in ICU continues.

Anahtar Kelime:

Konular: Biyoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157:121-41.
2. Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A 1998;95:6578-83.
3. de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012;70(Suppl 1):S45-56.
4. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489:220-30.
5. Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol 2012;2:104.
6. Waldor MK, Tyson G, Borenstein E, Ochman H, Moeller A, Finlay BB, et al. Where next for microbiome research? PLoS Biol 2015;13:e1002050.
7. Jumpstart Consortium Human Microbiome Project Data Generation Working Group. Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One 2012;7:e39315.
8. Borre YE, O’Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med 2014;20:509-18.
9. Hornig M. The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness. Curr Opin Rheumatol 2013;25:488-95.
10. Fetissov SO, Déchelotte P. The new link between gut-brain axis and neuropsychiatric disorders. Curr Opin Clin Nutr Metab Care 2011;14:477-82.
11. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007;104:979-84.
12. Round JL, O’Connell RM, Mazmanian SK. Coordination of tolerogenic immune responses by the commensal microbiota. J Autoimmun 2010;34:J220-5.
13. Costello EK, Stagaman K, Dethlefsen L, Bohannan BJ, Relman DA. The application of ecological theory toward an understanding of the human microbiome. Science 2012;336:1255-62.
14. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012;336:489-93.
15. Dinan TG, Quigley EM. Probiotics in the treatment of depression: science or science fiction? Aust N Z J Psychiatry 2011;45:1023-5.
16. Çelebi G, Uygun A. İntestinal mikrobiyota ve fekal transplantasyon. Güncel Gastroentoroloji 2013;17:148-57.
17. Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012;73:1128-38.
18. Maes M, Kenis G, Kubera M, De Baets M, Steinbusch H, Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int Immunopharmacol 2005;5:609-18.
19. Levkovich T, Poutahidis T, Smillie C, Varian BJ, Ibrahim YM, Lakritz JR, et al. Probiotic bacteria induce a ‘glow of health’. PLoS One 2013;8:e53867.
20. Dickson RP. The microbiome and critical illness. Lancet Respir Med 2016;4:59-72. 21. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature 2011;472:32.
22. Ducel G, Fabry J, Nicolle L, World Health Organization. Prevention of hospitalacquired infections: a practical guide. 2002.
23. Gabanyi I, Muller PA, Feighery L, Oliveira TY, Costa-Pinto FA, Mucida D. Neuroimmune Interactions Drive Tissue Programming in Intestinal Macrophages. Cell 2016;164:378-91.
24. Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 2013;13:321-35.
25. Pamer EG. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 2016;352:535-8.
26. Marshall JC, Christou NV, Meakins JL. The gastrointestinal tract. The “undrained abscess” of multiple organ failure. Ann Surg 1993;218:111-9.
27. Lu Q, Xu DZ, Sharpe S, Doucet D, Pisarenko V, Lee M, et al. The anatomic sites of disruption of the mucus layer directly correlate with areas of trauma/ hemorrhagic shock-induced gut injury. J Trauma 2011;70:630-5.
28. Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007;2:204.
29. Wolff NS, Hugenholtz F, Wiersinga WJ. The emerging role of the microbiota in the ICU. Crit Care 2018;22:78.
30. Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota. FEMS Microbiol Rev 2014;38:996-1047.
31. Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and ‘dysbiosis therapy’ in critical illness. Curr Opin Crit Care 2016;22:347-53.
32. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-74.
33. Lankelma JM, Belzer C, Hoogendijk AJ, de Vos AF, de Vos WM, van der Poll T, et al. Antibiotic-Induced Gut Microbiota Disruption Decreases TNF-α Release by Mononuclear Cells in Healthy Adults. Clin Transl Gastroenterol 2016;7:e186.
34. Clemente JC, Pehrsson EC, Blaser MJ, Sandhu K, Gao Z, Wang B, et al. The microbiome of uncontacted Amerindians. Sci Adv 2015;1. pii: e1500183.
35. Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr 2007;137(Suppl 2):S751-5.
36. Guarner F. Enteric flora in health and disease. Digestion 2006;73(Suppl 1):5- 12.
37. Lankelma JM, van Vught LA, Belzer C, Schultz MJ, van der Poll T, de Vos WM, et al. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intensive Care Med 2017;43:59-68.
38. McDonald D, Ackermann G, Khailova L, Baird C, Heyland D, Kozar R, et al. Extreme Dysbiosis of the Microbiome in Critical Illness. mSphere 2016;1. pii: e00199-16.
39. Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 2016;65:575-83.
40. Yooseph S, Kirkness EF, Tran TM, Harkins DM, Jones MB, Torralba MG, et al. Stool microbiota composition is associated with the prospective risk of Plasmodium falciparum infection. BMC Genomics 2015;16:631.
41. Lankelma JM, Birnie E, Weehuizen TAF, Scicluna BP, Belzer C, Houtkooper RH, et al. The gut microbiota as a modulator of innate immunity during melioidosis. PLoS Negl Trop Dis 2017;11:e0005548.
42. Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol 2017;10:299-306.
43. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017;15:55-63.
44. Marsland BJ, Trompette A, Gollwitzer ES. The Gut-Lung Axis in Respiratory Disease. Ann Am Thorac Soc 2015;12(Suppl 2):S150-6.
45. Deitch EA. Gut-origin sepsis: evolution of a concept. Surgeon 2012;10:350-6.
46. Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. Trends Mol Med 2014;20:214-23.
47. Earley ZM, Akhtar S, Green SJ, Naqib A, Khan O, Cannon AR, et al. Burn Injury Alters the Intestinal Microbiome and Increases Gut Permeability and Bacterial Translocation. PLoS One 2015;10:e0129996.
48. Iapichino G, Callegari ML, Marzorati S, Cigada M, Corbella D, Ferrari S, et al. Impact of antibiotics on the gut microbiota of critically ill patients. J Med Microbiol 2008;57:1007-14.
49. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012;55:905-14.
50. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycinresistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010;120:4332-41.
51. Deshmukh HS, Liu Y, Menkiti OR, Mei J, Dai N, O’Leary CE, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 2014;20:524-30.
52. Tsutsumi R, Horikawa YT, Kume K, Tanaka K, Kasai A, Kadota T, et al. Whey PeptideBased Formulas With ω-3 Fatty Acids Are Protective in LipopolysaccharideMediated Sepsis. JPEN J Parenter Enteral Nutr 2015;39:552-61.
53. Li Q, Wang C, Tang C, He Q, Zhao X, Li N, et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care 2015;19:37.
54. Wei Y, Yang J, Wang J, Yang Y, Huang J, Gong H, et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care 2016;20:332.
55. Zakharkina T, Martin-Loeches I, Matamoros S, Povoa P, Torres A, Kastelijn JB, et al. The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax 2017;72:803-10.
56. Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176-84.
57. Poroyko V, Meng F, Meliton A, Afonyushkin T, Ulanov A, Semenyuk E, et al. Alterations of lung microbiota in a mouse model of LPS-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2015;309:L76-83.
58. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003;111:1589-602.
59. Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, et al. Intraalveolar Catecholamines and the Human Lung Microbiome. Am J Respir Crit Care Med 2015;192:257-9.
60. Price R, MacLennan G, Glen J; SuDDICU Collaboration. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis. BMJ 2014;348:g2197.
61. Hotel ACP, Cordoba A. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention 2001;5:1-34.
62. Manzanares W, Wischmeyer PE. Erratum to: Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit Care 2017;21:42.
63. Li Q, Wang C, Tang C, He Q, Zhao X, Li N, et al. Therapeutic modulation and reestablishment of the intestinal microbiota with fecal microbiota transplantation resolves sepsis and diarrhea in a patient. Am J Gastroenterol 2014;109:1832-4.
64. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013;29:79-84.
65. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-14.
66. Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc 2016;49:257-65.
67. Fukuda K, Ogawa M, Taniguchi H, Saito M. Molecular Approaches to Studying Microbial Communities: Targeting the 16S Ribosomal RNA Gene. J UOEH 2016;38:223-32.
68. Altındiş. M. Mikrobiyata Çalıştayı Sonu Bildirgesi. Sakarya: University of Sakarya; 2017.

APA	PEHLİVANLAR Küçük M, Ülger F (2019). Mikrobiyota ve Yoğun Bakım. , 122 - 129. 10.4274/tybd.galenos.2019.70883
Chicago	PEHLİVANLAR Küçük Mehtap,Ülger Fatma Mikrobiyota ve Yoğun Bakım. (2019): 122 - 129. 10.4274/tybd.galenos.2019.70883
MLA	PEHLİVANLAR Küçük Mehtap,Ülger Fatma Mikrobiyota ve Yoğun Bakım. , 2019, ss.122 - 129. 10.4274/tybd.galenos.2019.70883
AMA	PEHLİVANLAR Küçük M,Ülger F Mikrobiyota ve Yoğun Bakım. . 2019; 122 - 129. 10.4274/tybd.galenos.2019.70883
Vancouver	PEHLİVANLAR Küçük M,Ülger F Mikrobiyota ve Yoğun Bakım. . 2019; 122 - 129. 10.4274/tybd.galenos.2019.70883
IEEE	PEHLİVANLAR Küçük M,Ülger F "Mikrobiyota ve Yoğun Bakım." , ss.122 - 129, 2019. 10.4274/tybd.galenos.2019.70883
ISNAD	PEHLİVANLAR Küçük, Mehtap - Ülger, Fatma. "Mikrobiyota ve Yoğun Bakım". (2019), 122-129. https://doi.org/10.4274/tybd.galenos.2019.70883

APA	PEHLİVANLAR Küçük M, Ülger F (2019). Mikrobiyota ve Yoğun Bakım. Türk Yoğun Bakım Dergisi, 17(3), 122 - 129. 10.4274/tybd.galenos.2019.70883
Chicago	PEHLİVANLAR Küçük Mehtap,Ülger Fatma Mikrobiyota ve Yoğun Bakım. Türk Yoğun Bakım Dergisi 17, no.3 (2019): 122 - 129. 10.4274/tybd.galenos.2019.70883
MLA	PEHLİVANLAR Küçük Mehtap,Ülger Fatma Mikrobiyota ve Yoğun Bakım. Türk Yoğun Bakım Dergisi, vol.17, no.3, 2019, ss.122 - 129. 10.4274/tybd.galenos.2019.70883
AMA	PEHLİVANLAR Küçük M,Ülger F Mikrobiyota ve Yoğun Bakım. Türk Yoğun Bakım Dergisi. 2019; 17(3): 122 - 129. 10.4274/tybd.galenos.2019.70883
Vancouver	PEHLİVANLAR Küçük M,Ülger F Mikrobiyota ve Yoğun Bakım. Türk Yoğun Bakım Dergisi. 2019; 17(3): 122 - 129. 10.4274/tybd.galenos.2019.70883
IEEE	PEHLİVANLAR Küçük M,Ülger F "Mikrobiyota ve Yoğun Bakım." Türk Yoğun Bakım Dergisi, 17, ss.122 - 129, 2019. 10.4274/tybd.galenos.2019.70883
ISNAD	PEHLİVANLAR Küçük, Mehtap - Ülger, Fatma. "Mikrobiyota ve Yoğun Bakım". Türk Yoğun Bakım Dergisi 17/3 (2019), 122-129. https://doi.org/10.4274/tybd.galenos.2019.70883